Emyria Limited (ASX: EMD) has reported Emyria PTSD Treatment Results showing 67% of patients achieving clinical remission 12+ months after completing treatment. The mental health treatment company’s latest data, released 2 February 2026, demonstrates that 76% of patients experienced clinically significant improvements, with a median recovery time of approximately 28 days.
Two-thirds of patients achieve lasting PTSD remission
The Emyria PTSD Treatment Results reveal sustained clinical outcomes among a highly treatment-resistant patient cohort. According to the company’s 12-month follow-up data as at 31 December 2025, 67% of patients remain in clinical remission, with PTSD symptom scores staying below the diagnostic threshold.
The data shows 50% of patients reached remission within 28 days of the start of treatment, with an additional ~16% achieving remission during the follow-up period. Patients were measured using the PCL-5 scale, with scores of 32 or below indicating clinical remission.
This patient population presented with severe, long-standing symptoms and had failed multiple previous treatments. The durability of response stands in contrast to standard PTSD therapies, which typically experience dropout rates of 20-40%.
“Seeing two-thirds of patients with severe, treatment-resistant PTSD achieve lasting recovery is clinically significant. The durability of these results suggests we’re facilitating genuine recovery, not temporary symptom suppression,” said Dr Jon Laugharne, Medical Director.
Understanding PTSD treatment measurement
The PCL-5 (PTSD Checklist for DSM-5) is an internationally recognised assessment tool used to measure PTSD symptom severity. This standardised metric provides comparable, objective data that supports clinical validation and regulatory discussions.
Clinical remission occurs when a patient’s PCL-5 score falls to 32 or below, indicating symptoms have dropped beneath the diagnostic threshold for PTSD. The measurement framework enables consistent tracking across patient cohorts and facilitates comparison with other treatment modalities.
The emphasis on durable outcomes matters because temporary symptom relief often fails to address the underlying condition. Emyria’s data demonstrates that patients who achieved remission generally maintained those improvements at subsequent follow-up assessments, indicating sustained clinical benefit rather than transient response.
Commercial pipeline building momentum
Emyria (ASX: EMD) has established commercial traction across its treatment programmes, with 100+ patients screened and seeking treatment as at 31 December 2025. Many of these patients have private health insurance funding support.
Since programme inception in November 2023, 40+ patients have completed the PTSD treatment programme. The forward pipeline shows continued demand, with 67 patients booked for screening in Q1 CY2026 across both PTSD and depression treatment programmes.
Key commercial metrics include:
- 100+ patients screened and seeking treatment (as at 31 December 2025)
- 40+ patients completed the PTSD programme since November 2023
- 67 patients booked for Q1 2026 screening
- Expansion into depression treatment programmes alongside PTSD services
The company reports that private health insurers currently fund Emyria’s programmes, with increasing engagement from government-linked payers as long-term outcome data emerges.
Why durable outcomes matter for payers
The Emyria PTSD Treatment Results carry financial implications for healthcare payers beyond clinical efficacy. Durable clinical outcomes translate to reduced lifetime healthcare costs through lower relapse rates, decreased hospitalisation, and reduced dependence on ongoing treatments that deliver limited benefit.
Private health insurers already provide funding support for Emyria’s programmes. As longitudinal data demonstrates sustained remission at 12+ months, government-linked payers have shown increasing engagement with the company’s treatment model.
| Metric | Emyria Programme | Standard PTSD Therapy |
|---|---|---|
| Remission Rate | ~67% | Variable |
| Dropout Rate | Zero reported | 20-40% |
| Time to Remission | ~28 days median | Months to years |
| Durability at 12+ months | Sustained sub-clinical scores | Often requires ongoing treatment |
The data supports a sustainable reimbursement model by demonstrating that initial treatment investment produces lasting clinical benefit. This cost-effectiveness profile contrasts with therapies requiring continuous intervention to maintain symptom management.
The Australian PTSD treatment opportunity
PTSD represents a substantial component of Australia’s mental health burden, affecting a significant portion of the population:
- 1 in 11 Australians experience PTSD during their lifetime
- 17%+ of transitioned defence force veterans affected in any 12-month period
Many patients fail to achieve lasting recovery with existing treatments, creating considerable unmet need within the healthcare system. The treatment-resistant nature of many PTSD cases results in ongoing healthcare utilisation and associated costs without corresponding clinical improvement.
Emyria’s approach targets this gap by focusing on patients for whom conventional therapies have failed. The company’s real-world data demonstrates clinical outcomes in this challenging population, validating the commercial opportunity within a large addressable market with existing payer interest.
Building a scalable treatment platform
Emyria is constructing a data-driven platform that supports geographic expansion and protocol refinement. The company generates real-world evidence through its clinical services, which informs ongoing programme improvement and creates a competitive advantage through continuous learning.
The longitudinal outcome framework initially developed for PTSD treatment has been extended to the company’s depression programmes. This systematic approach to evidence generation supports practitioner confidence and patient acquisition as the treatment model demonstrates consistent results.
“That the majority of patients undergoing Emyria’s treatments are achieving durable and often immediate benefit is impactful, not just for the patient, but also for their families and friends. It’s also important to other stakeholders in the mental healthcare system, from practitioners who are witnessing previously inaccessible results, to payers seeking more cost-effective options. We’re building a data-driven platform that is driving practitioner and patient acquisition, and sustainable geographic growth across a nation-wide clinic network,” said Greg Hutchinson, Executive Chair.
The company’s integrated model combines Emyria Healthcare (clinical service delivery), Emyria Data (real-world evidence generation), and Emyria Pipeline (therapy and drug development). This structure enables clinical insights to inform protocol refinement while supporting the commercial expansion of validated treatment programmes across a nationwide clinic network.
Want more Biotech breakthroughs like this?
The Emyria PTSD Treatment Results represent exactly the kind of data-driven clinical progress that defines Australia’s emerging biotech sector. When a listed company reports 67% remission rates in treatment-resistant patients with 12+ month durability, it signals genuine commercial potential backed by measurable outcomes. For investors tracking the ASX biotech and healthcare space, these are the developments that separate speculative positioning from evidence-based opportunities.
StockWire X delivers FREE breaking news and comprehensive analysis across non-resource ASX sectors including Biotech, Healthcare, Technology, Finance, and Industrials. Join 20,000+ investors who receive Big News Blasts covering market-moving announcements with the context needed to assess commercial significance. Click the “Free Alerts” button in the menu to receive these updates directly to your inbox.